文献速递头颈与中枢神经肿瘤

诱导化疗后放疗对比放化疗治疗鼻咽癌:一项随机临床试验

Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2024-01-01

这项多中心、开放标签、随机、非劣效性3期试验纳入383例局部晚期鼻咽癌患者,比较诱导化疗后单纯放疗与同步放化疗的疗效。意向治疗人群中,IC-RT组与IC-CCRT组3年无进展生存率分别为76.2%和76.8%,差异0.6%(95%CI -7.9%至9.1%),非劣效性P=0.01。IC-RT组3-4级短期毒性反应发生率低于IC-CCRT组。

要点

  • 诱导化疗后单纯放疗在3年无进展生存方面非劣效于同步放化疗。
  • IC-RT组3-4级短期毒性反应发生率低于IC-CCRT组。
  • 两组晚期毒性反应无差异。

核心结论

  • 对于局部晚期鼻咽癌,诱导化疗后单纯放疗在3年无进展生存方面非劣效于同步放化疗。

研究设计与样本

  • 2015年4月至2018年3月在中国5家医院开展的多中心、开放标签、随机、非劣效性3期试验。
  • 共纳入383例年龄18至70岁、未经治疗、组织学确诊非角化性肿瘤、Karnofsky体能状态评分不低于70、器官功能正常、III至IVB期鼻咽癌患者。
  • 数据分析时间为2023年4月至2023年6月。

主要发现

  • 中位随访时间76个月(IQR 70-89个月);患者中位年龄48岁(范围19-70岁),女性100例(26%)。
  • 意向治疗人群中,IC-RT组(n=193)3年无进展生存率为76.2%,IC-CCRT组(n=190)为76.8%,差异0.6%(95%CI -7.9%至9.1%),非劣效性P=0.01。
  • 符合方案人群报告了相同的结果。
  • IC-RT组3-4级短期毒性反应发生率低于IC-CCRT组。
  • 两组晚期毒性反应无差异。

关键数值与推荐

  • 两组均接受3周期诱导化疗:第1天静脉给予顺铂60 mg/m2和多西他赛60 mg/m2,第1天至第5天持续静脉输注每日氟尿嘧啶600 mg/m2,每21天重复一次。
  • 随后IC-RT组接受单纯放疗;IC-CCRT组接受同步顺铂(30 mg/m2/周)联合放疗,持续6至7周。
  • 主要终点为3年无进展生存,非劣效性界值为10%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Induction chemotherapy plus concurrent chemoradiotherapy is recommended for locoregionally advanced nasopharyngeal carcinoma but is associated with higher rates of acute toxic effects and low compliance. Evidence on de-escalating treatment intensity after induction chemotherapy is limited. OBJECTIVE: To assess if radiotherapy was noninferior to chemoradiotherapy after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma. DESIGN, SETTING, AND PARTICIPANTS: From April 2015 to March 2018, a multicenter, open-label, randomized, noninferiority, phase 3 trial was conducted at 5 Chinese hospitals. A total of 383 patients aged 18 to 70 years with an untreated histologically confirmed nonkeratinizing tumor, Karnofsky performance status score not worse than 70, proper organ function, and stage III to IVB nasopharyngeal cancer were enrolled. Data were analyzed from April 2023 to June 2023. INTERVENTIONS: Patients were assigned randomly. Both groups received 3 cycles of induction chemotherapy consisting of intravenous administration (on day 1) of cisplatin at 60 mg/m2 and docetaxel at 60 mg/m2 and continuous intravenous infusion (from day 1 to day 5) of daily fluorouracil (600 mg/m2), repeated every 21 days. Subsequently, the patients received radiotherapy alone (induction chemotherapy in combination with radiotherapy [IC-RT] group) or concomitant cisplatin (30 mg/m2/week) with radiotherapy for 6 to 7 weeks (induction chemotherapy combined with chemoradiotherapy [IC-CCRT] group). MAIN OUTCOMES AND MEASURES: The primary end point was 3-year progression-free survival (time from the initiation of therapy until the first indication of disease progression or death), with a noninferiority margin of 10%. The secondary end points included overall survival, locoregional failure-free survival, distant metastasis-free survival, response rate, and toxic effects. RESULTS: A total of 383 patients (median [range] age, 48 [19-70] years; 100 women [26%]). Median follow-up time was 76 months (IQR, 70-89 months). The 3-year progression-free survival was 76.2% and 76.8% in the IC-RT (n = 193) and IC-CCRT groups (n = 190), respectively, in the intention-to-treat population, showing a difference of 0.6% (95% CI, -7.9% to 9.1%; P = .01 for noninferiority). Identical outcomes were reported in the per-protocol population. The incidence of grade 3 to 4 short-term toxic effects in the IC-RT group was less than the IC-CCRT group. No differences were observed in late toxic effects. CONCLUSIONS AND RELEVANCE: The results of this randomized clinical trial suggest that after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma, radiotherapy alone was noninferior to chemoradiotherapy in terms of 3-year progression-free survival. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02434614.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Dai J, Zhang B, Su Y, et al. Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA Oncol. 2024. PMID: 38329737. doi:10.1001/jamaoncol.2023.6552

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。